Quantum BioPharma Advances Multiple Sclerosis Drug Toward Phase 2 Clinical Trial
TL;DR
Quantum BioPharma gains advantage by signing agreement for Lucid-MS IND application, positioning for Phase 2 clinical trial for multiple sclerosis treatment.
Quantum BioPharma partners with global CRO to submit Lucid-MS IND to FDA in Q4 2025, aiming to prevent demyelination in MS and neurodegenerative disorders.
Quantum BioPharma's Lucid-MS therapy could improve lives by halting myelin degradation, offering hope for better treatments in neurodegenerative diseases like MS.
Quantum BioPharma's innovative approach to neuroprotection with Lucid-MS shows promise in addressing the complex mechanisms of multiple sclerosis and other disorders.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantum BioPharma Ltd. has taken a significant step toward developing a novel treatment for multiple sclerosis by signing an agreement with a global pharmaceutical contract research organization to prepare an Investigational New Drug (IND) application for its lead compound, Lucid-21-302.
The company plans to submit the IND to the U.S. Food and Drug Administration in the fourth quarter of 2025, with the goal of initiating a Phase 2 clinical trial. Lucid-21-302, also known as Lucid-MS, represents a potential breakthrough in MS treatment as a patented, non-immunomodulatory neuroprotective therapy.
Preclinical studies have demonstrated the compound's ability to prevent demyelination, a critical mechanism in multiple sclerosis and other neurodegenerative disorders. By targeting myelin degradation, the drug could offer a new approach to managing and potentially halting disease progression.
This development is significant for patients with multiple sclerosis, a chronic neurological condition that currently lacks comprehensive treatment options. If successful, Lucid-21-302 could provide a novel therapeutic strategy that differs from existing immunomodulatory treatments by focusing on neuroprotection.
The advancement of Lucid-MS through the regulatory process represents an important milestone for Quantum BioPharma and potentially offers hope for improved management of multiple sclerosis and related neurodegenerative conditions.
Curated from InvestorBrandNetwork (IBN)
